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 Coronavirus disease 2019 (COVID-19) has caused more than 32 million cases and almost a million deaths. Recent 
reviews have evidenced the role of hypertension in prognosis, nevertheless, its association with 
immunosuppression in COVID-19 context has not been studied. It was performed a cross-sectional analysis of a 
large Mexican population with the infection (n= 681 890). Prevalence of immunosuppression and hypertension 
was 1.10% and 19.50%, respectively. The adjusted model evidenced that hypertension was significantly 
associated with immunosuppression (odds ratio=1.18, 95% CI=1.11-1.25). Further research in pathways that justify 
the association between hypertension and immunosuppression in COVID-19 patients is recommended. 
Keywords: hypertension, COVID-19, severe acute respiratory syndrome coronavirus 2, Mexico, public health 
 
Dear editor, 
Up to the date, coronavirus disease 2019 (COVID-19), which 
is caused by the severe acute respiratory syndrome 
coronavirus 2 (SARS-CoV-2), has caused more than 32 million 
cases and almost a million deaths [1]. Moreover, several studies 
have proposed the role of non-communicable diseases (NCDs) 
in evolution and prognosis of COVID-19. 
A previous meta-analysis reported that hypertension is one 
of the most frequent NCDs in infected patients, moreover, it 
was significantly associated with severe COVID-19 [2]. 
Regarding biological plausibility, it is postulated that 
coronaviruses down-regulate the pulmonary angiotensin-
converting enzyme 2 receptors, which leads to a subsequent 
accumulation of angiotensin II [3]. This accumulation may 
contribute to pulmonary damage, and increased blood 
pressure [3]. Indeed, results from a recent systematic review 
suggested that anti-hypertensive medication reduces COVID-
19 mortality [4]. It is known that several NCDs are related to 
immunosuppression, which worsens COVID-19 severity, 
nevertheless, the association between it and hypertension has 
not been established in the population of interest. Therefore, 
we aimed to identify this association in the Mexican 
population. 
It was performed a cross-sectional analysis of the database 
released by the Secretaría de Salud de México, which covered 
the period ending on May 18, 2020. Analyses in this paper were 
limited to this date. The database was freely available at 
https://bit.ly/308Yu4y, and it registered variables of patients 
who were tested for SARS-CoV-2. 
The dependent variable was immunosuppression (yes or 
no). It is defined as the presence of low markers of immune 
response. The independent variable was the existence of 
hypertension (yes or no). Two logistic regression models 
(unadjusted and adjusted) were performed to identify the 
association between both variables. The second model was 
adjusted for all potential confounders: age, sex, diabetes, 
chronic obstructive pulmonary disease, obesity, pneumonia, 
smoking history, and other cardiovascular diseases. Analyses 
were done using Stata v.16 (College Station, TX: StataCorp 
LLC). 
Data from 1 048 575 patients was originally reported in the 
database. Prevalence of positive SARS-CoV-2 infection was 
65.24% (n=684 113). After excluding missing data in both 
dependent and independent variables, 681 890 patients with 
positive infection were included in this study.  
Male sex accounted for 52.09%. The mean age was 44.77 
(standard deviation= 16.65). Prevalence of 
immunosuppression was 1.10% (n=7 485). Moreover, 
hypertension accounted for 19.50% (n=132 974).  
It was found a significant association between 
hypertension and immunosuppression in patients with 
positive SARS-CoV-2 both in the unadjusted [OR=2.13, 95% 
confidence interval (CI) =2.03-2.24] and adjusted models 
(OR=1.18, 95% CI=1.11-1.25) (Table 1). 
Table 1. Association between hypertension and 
immunosuppression in patients with positive SARS-CoV-2 
Variable OR CI 95% P value 
Unadjusted     
Non hypertension Reference - 
Hypertension 2.13 2.03-2.24 <0.001 
Adjusted1     
Non hypertension Reference - 
Hypertension 1.18 1.11-1.25 <0.001 
OR: odds ratio. CI: confidence interval. 
1This model was adjusted for age, sex, diabetes, chronic obstructive 
pulmonary disease, obesity, pneumonia, smoking history, and other 
cardiovascular diseases. 
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Our findings suggest that hypertension could be associated 
with a greater likelihood of immunosuppression in Mexican 
patients with SARS-CoV-2 infection. Hypertensive changes are 
associated with chronic inflammation that not only triggers 
endothelial dysfunction, but production of reactive oxygen 
species [5]. A baseline pro-inflammatory context may increase 
the risk of immunosuppression in COVID-19 patients. 
Hypertension accounts up to 40% of cases worldwide, and 
it is associated with lethal disease, especially in developing 
countries [5]. Consequently, care prioritization of infected 
patients at higher risk of complications, such as hypertensive 
patients, is necessary to reduce inflation of deaths. Finally, it is 
recommended further research in pathways that justify the 
association between hypertension and immunosuppression in 
COVID-19 patients. 
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